New study aims to personalize throat cancer treatment using genetic tests and MRI
NCT ID NCT07407205
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether genetic markers (like tumor mutations and DNA in the blood) and special MRI scans can predict how well chemoradiotherapy works for patients with HPV-negative oropharyngeal cancer. Researchers will follow 30 patients to see if these tests can forecast treatment response and disease progression. The goal is to tailor therapy and reduce the number of follow-up scans needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which patients will respond best to chemoradiotherapy, potentially personalizing treatment and reducing unnecessary scans.
What could go wrong
This is a small, early-stage study with only 30 participants, so results may not apply to everyone. The biomarkers being tested may not reliably predict outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia